home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408a.zip
/
M9480212.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
3KB
|
45 lines
Document 0212
DOCN M9480212
TI Frequent and early HIV-1MN neutralizing capacity in sera from Dutch
HIV-1 seroconverters is related to antibody reactivity to peptides from
the gp120 V3 domain.
DT 9410
AU Zwart G; Back NK; Ramautarsing C; Valk M; van der Hoek L; Goudsmit J;
Department of Virology, University of Amsterdam, The Netherlands.
SO AIDS Res Hum Retroviruses. 1994 Mar;10(3):245-51. Unique Identifier :
AIDSLINE MED/94289062
AB The temporal development of HIV-1 neutralizing activity and antibodies
to the gp120-V3 neutralization domain were studied in sera from 20 Dutch
HIV-1-infected individuals followed from seroconversion on. Serum
neutralizing capacity was assessed with three T cell line-tropic
isolates: HIV-1MN, HIV-1HXB2, and the patient isolate HIV-1(320).
Neutralizing activity to HIV-1MN developed in 18 individuals (90%)
within 0 to 10 months after seroconversion. Parallel evolution of IgG
reactivity to V3 peptides of United States/European type variants, and
the capability of such peptides to completely inhibit HIV-1MN
neutralization in four of five tested sera (taken 1-2 years after
seroconversion), indicate that a large proportion of HIV-1MN
neutralizing antibodies is directed to V3. The early appearance and high
frequency of HIV-1MN neutralizing activity in the Dutch study group
indicate the close relationship of HIV-1MN to HIV-1 variants circulating
in the Netherlands. Neutralizing activity to HIV-1HXB2 (in 15 of 20
individuals) developed several months after that to HIV-1MN in all
individuals (average, 10 months after seroconversion) and was not seen
in the absence of HIV-1MN neutralizing activity. Neutralizing activity
to the Dutch isolate HIV-1(320) (found in 11 of 18 tested individuals)
emerged simultaneously with that to HIV-1MN in 4 individuals but
appeared later in 7. In most individuals, HIV-1HXB2 neutralization was
not accompanied by reactivity to a V3 peptide from this strain,
indicating that the extension of neutralizing activity to more divergent
strains, which takes place at later stages, must be attributed to
non-V3-directed antibodies.
DE Adult Amino Acid Sequence Human HIV Antibodies/*IMMUNOLOGY HIV
Envelope Protein gp120/*IMMUNOLOGY HIV
Seropositivity/*BLOOD/MICROBIOLOGY HIV-1/CLASSIFICATION/*IMMUNOLOGY
IgG/IMMUNOLOGY Male Molecular Sequence Data Neutralization Tests
Peptide Fragments/*IMMUNOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).